Table 4 HER2 , TOP2A and CEP17 status and TopoIIa protein expression according to breast cancer subtypes defined by immunohistochemistry
Luminal A | Luminal B | Luminal-HER2 | HER2-enriched | TNBC | |
|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | |
FISH | |||||
HER2 gene status | |||||
Non-amplified | 242 (100.0) | 386 (100.0) | 3 (2.2) | 1 (0.9) | 126 (100.0) |
Amplified | 0 | 0 | 135 (97.8) | 107 (99.1) | 0 |
TOP2A gene status | |||||
Deleted | 5 (2.1) | 15 (3.9) | 12 (8.7) | 11 (10.2) | 8 (6.3) |
Non-amplified | 236 (97.5) | 371 (96.1) | 65 (47.1) | 55 (50.9) | 118 (93.7) |
Amplified | 1 (0.4) | 0 | 61 (44.2) | 42 (38.9) | 0 |
CEP17 status | |||||
No gain | 149 (61.6) | 234 (60.6) | 70 (50.7) | 50 (46.3) | 93 (73.8) |
Gain | 93 (38.4) | 152 (39.4) | 68 (49.3) | 58 (53.7) | 33 (26.2) |
IHC | |||||
TopoIIa | |||||
Negative | 165 (73.7) | 130 (35.2) | 48 (36.9) | 43 (41.7) | 49 (42.6) |
Positive | 59 (26.3) | 239 (64.8) | 82 (63.1) | 60 (58.3) | 66 (57.4) |